"AI can shorten drug-discovery timelines, but the bench-to-clinic gap remains India's real bottleneck." Discuss, with reference to recent state-backed financing of AI-led drug development.

The bench-to-clinic gap is the costly stretch between a promising molecule and a drug ready for human trials. In technology terms it runs roughly from TRL-4 to TRL-6 and covers validation, preclinical work and IND-enabling studies. AI speeds up discovery, but for India the harder problem is this translation stage.

How AI shortens discovery

• AI helps identify promising molecules, map disease mechanisms and speed up the search for therapies [1].
• One platform can produce several candidates. Peptris's platform produced four, for alopecia, neuropathy, DMD and oncology [1].

Why bench-to-clinic remains the bottleneck

• Financing gap: Private firms fund only about 36% of India's GERD, and the government funds about 64% [4]. Startups have little collateral to borrow against at a stage that earns no revenue.
• Translation capacity: The VIGOR project relies on global CRO networks for its studies [1], which shows that India has limited capacity of its own for preclinical and clinical work.
• Regulation: A molecule found by AI must still clear the full preclinical and IND process [1]. WHO notes that most countries lack specific guidance on AI in health, and it stresses transparency and accountability [5].

State-backed financing as a bridge

• RDI Scheme: It has a corpus of ₹1 lakh crore over six years and funds projects at TRL-4 and above [2].
• TDB–Peptris (VIGOR): TDB is providing ₹86 crore of a ₹172 crore project as Optionally Convertible Debt. The aim is to take four AI-discovered candidates from TRL-4 to TRL-6 in three years [1].
• Recyclable design: The scheme gives loans and equity, not grants [2][3]. Public money can be repaid or turned into a stake, and private capital is at risk alongside it.
• Limits: Money is reaching firms slowly. The two second-level fund managers, TDB and BIRAC, have been sanctioned ₹1,000 crore each [3]. The release also publishes no pricing or access terms, even for rare-disease candidates [1].

Way forward

• CDSCO guidance on how AI-generated evidence can be used in IND filings [5].
• Access conditions linked to the National Policy for Rare Diseases, 2021.
• Building domestic GLP and CRO capacity, and faster onboarding of fund managers.

AI has made finding drug candidates easier, but moving them from lab to clinic is still India's real constraint. Patient risk capital, clear regulation and domestic capacity for trials can turn deals like VIGOR from exceptions into a pipeline. That would advance SDG 3 (good health) and SDG 9 (industry and innovation), and support the constitutional promise of public health.